On November 6, 2018, Luoyang Huizhong Biotechnology Co., Ltd. (a wholly-owned subsidiary of Plyco Bioengineering Co., Ltd.) relied on the water adjuvant porcine circovirus 2 developed by the National Engineering Research Center for Veterinary Medicine for 8 years The press conference for the launch of the combined inactivated vaccine against mycoplasma hyopneumoniae and mycoplasma was held in Luoyang.

"Porcine circovirus type 2 and Mycoplasma hyopneumoniae dual inactivated vaccine" is Huizhong Biotechnology Co., Ltd. adhering to the business philosophy of "decent and stable operation", pursuing the development strategy of "innovating for the future" and relying on the national veterinary drug project. The Technology Research Center has achieved major scientific and technological achievements for the technology platform, has independent intellectual property rights, and has obtained the national new veterinary drug registration certificate. This result is another masterpiece obtained through continuous innovative practice since Huizhong's biological adjuvant porcine circovirus type 2 inactivated vaccine (SH strain II)!

In recent years, with the continuous deepening of my country’s agricultural and animal husbandry industrialization reforms, it has facilitated the sustainable development of my country’s animal husbandry. The species and number of livestock and poultry have increased significantly, and the types and frequency of livestock and poultry diseases have also increased. greatly increase. In clinical morbidity, mixed infection is a common phenomenon, especially the mixed infection of circovirus type 2 and Mycoplasma hyopneumoniae is more common. Therefore, the combined vaccine that can prevent multiple diseases is the current development trend of veterinary biological products, and it is also a breeding enterprise. Urgently needed products. Although there are mature commercial vaccines for the prevention and control of these two pathogens, there are many types and complicated immune procedures. Therefore, the combined vaccine of circovirus type 2 and Mycoplasma hyopneumoniae can make up for the single vaccine in the application process. A series of shortcomings achieve the effect of one needle and two defenses, saving time and effort.

The "Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae Dual Inactivated Vaccine" launched by Huizhong Biotechnology has completely independent intellectual property rights. It is the first to complete product development and obtain a new veterinary drug certificate; special water adjuvants cooperate with advanced manufacturing The seedling technology guarantees the quality of the combined seedlings, and one injection and two preventions can effectively avoid the risks of adjuvant, antigen incompatibility, poor stability and uniformity after single seedlings are mixed.

1. Domestic isolated bacterial strains are more suitable for Chinese pig farms: Mycoplasma hyopneumoniae is selected domestically isolated popular strain HN0613. The nucleotide sequence analysis of the P97 gene R1 region shows that its homology rate with domestic isolated strains is much higher than that of foreign strains. Laboratory immune challenge and clinical use have proved that it has good immunogenicity and protection, more comprehensive protection, and more suitable for Chinese pig farms.

2. Antigen purification has no interference and solves compatibility problems: By optimizing the medium formula and fermentation parameters, it has broken through the process problems of mycoplasma high-density fermentation, and the culture level has reached a stable level of 5.0×109.0 CCU/ml. Through purification processes such as tangential flow ultrafiltration, the porcine circovirus type 2 antibody in the pig serum required for mycoplasma culture is completely removed, and the removal rate of contaminated proteins reaches 99%, which avoids interference with the immune effect of circovirus and solves the problem. Compatibility of the two antigens is difficult; PK15-B1 susceptible clonal cells are used to culture ring antigen, and the culture titer is ≥1.0×107.0TCID50/head. Through purification processes such as tangential flow ultrafiltration, the removal rate of contaminated proteins has reached more than 99%, and the antibody titer in the pig serum after immunization is equivalent to that of the imported vaccine.

3. Special water adjuvant is preferred, and dual antigens are suitable at the same time: The adjuvant of this product (FreemixTM-Gel adjuvant) uses colloidal polymer cross-linked copolymer as the material to prepare nano-microspheres with positive charge on the surface, which is adsorbed by static electricity. , It can effectively adsorb negatively charged PCV2 and mycoplasma antigens, and the adjuvant antigen complexes formed are easy to be recognized and processed by immune cells; more than 90% of the nanoparticles are within 1000 nanometers in diameter, which is easy to be quickly recognized by antigen-presenting cells, start and Activate a comprehensive immune response to ensure rapid immune protection after vaccine immunization; the interior of the nanoparticle is a spatial network structure, two antigens are chimeric in it, so as to achieve a long-term sustained release, and the immunity lasts for more than 4 months.